Custom crystal tombstone celebrating a second close of Series A financing for Fusion Pharmaceuticals. The Hamilton, Ontario-based firm is focused on radiotherapeutics for treating cancer.
(8ALJ479)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Custom crystal tombstone celebrating a second close of Series A financing for Fusion Pharmaceuticals. The Hamilton, Ontario-based firm is focused on radiotherapeutics for treating cancer.
(8ALJ479)Custom crystal tombstone marking a private placement by Swiss biopharmaceutical company Auris Medical. Ladenburg Thalmann acted as exclusive placement agent.
(8AMF064)Custom crystal commemorating a research collaboration involving Neurocrine Biosciences and Jnana Therapeutics. The research centers on finding new small-molecule therapeutics targeting central nervous system disorders.
(8ALJ498)Custom crystal deal toy commemorating a follow-on offering by EnteroMedics. Ladenburg Thalmann acted as sole bookrunning manager for the follow-on issue by the medical device developer. Based in St. Paul, Minnesota, the company was renamed ReShape Lifesciences in October 2017.
(7AMF287)Crystal deal toy marking a follow-on offering by InVivo Therapeutics. Headquartered in Cambridge, Massachusetts, the biotech firm specializes in the treatment of spinal cord injuries. Ladenburg Thalmann acted as sole bookrunner manager on the offering.
(8AMF234)Crystal tombstone marking the completion of Series E financing for Epic Sciences. Funding for the San Diego-based biotech and diagnostics firm was led by Blue Ox Healthcare Partners, a private equity firm based in New York.
(8ALJ481)Plasma-themed crystal deal toy marking two transactions involving German blood plasma firm Biotest.
(8LKC019)Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
